Healthcare specialist SHS Capital sells Spiegelberg, a leading medtech expert for devices and consumables in the field of neurosurgery, to Luciole Medical
- Spiegelberg GmbH & Co. KG is one of the leading suppliers in the field of manufacturing devices and consumables for intracranial pressure measurement and has been able to grow strongly in recent years
- Luciole Medical AG, which specialises in cerebral monitoring and measurement of oxygen saturation in the brain, is expanding its product range with the acquisition of Spiegelberg
Tübingen / June 27, 2023
German healthcare specialist SHS Capital is selling its shares in Spiegelberg to Luciole Medical AG. Spiegelberg, a medical technology company based in Hamburg, develops, produces and distributes highly specialised catheters and measuring probes for neurosurgical applications in the brain.
Founded in 1986, Spiegelberg has developed into a recognised provider in the field of intracranial pressure measurement. During the holding period of SHS, significant growth was generated. Today, the company is one of the leading manufacturers of ICP probes for intracranial pressure measurement and the production of high-quality catheters for ventricular drainage, subdural drainage or lumbar drainage and matching external ventricular drainage sets (EVD). The company works with recognised research institutes as well as leading clinics and specialists in neurosurgery to develop products that are best tailored to the patient.
With Luciole Medical AG, the company now has the opportunity to leverage strategic synergies, both in product development and in sales. The company’s products complement each other ideally, the sales channels and the target customers with neuroclinics, hospitals and special distributors are almost identical. Together, the companies can individualise and optimise the comprehensive monitoring of brain functions.
“We are delighted to have found a partner in Luciole Medical AG that will enable us to offer further innovative products on the market and thus achieve an even better market position,” said Spiegelberg CEO Stefan Paschko.
“Spiegelberg can be described as the perfect addition to our product portfolio. The significant growth of the company, the profitable core business, but also the strong international presence of the company, have convinced us. We are looking forward to the upcoming cooperation and the numerous opportunities we will develop together,” explains Luciole CEO Philippe Dro.
“We are pleased to now hand over our shares in Spiegelberg to a suitable partner after several successful years of cooperation. This merger is the ideal synergy of two innovative companies that will improve both market presence and treatment options in the field of cerebral health,” says SHS Managing Partner Uwe Steinbacher.
About Spiegelberg:
The medical technology company Spiegelberg GmbH & Co. KG, based in Hamburg, was founded in 1986 by Dr. Andreas Spiegelberg. Spiegelberg develops, produces and distributes products for intracranial pressure measurement, cerebrospinal fluid drainage and IAP measurement in more than sixty countries. The focus is on reliability, robustness and easy handling, so that the work is made easier and the treatment of the patient is the centre of attention.
More information at: www.spiegelberg.de
About SHS Gesellschaft für Beteiligungsmanagement mbH:
SHS Capital is a private equity provider founded in 1993 that invests in healthcare companies in Europe. The focus of the investments is on expansion financing, shareholder changes and succession situations. “Building European Healthcare Champions” is the investment philosophy according to which SHS finances and develops portfolio companies. The Tübingen-based investor takes both minority and majority stakes. The national and international investors in SHS funds include pension funds, funds of funds, foundations, family offices, strategic investors, entrepreneurs and the SHS management team. The equity or equity-like investment of the AIF is up to € 40 million. Volumes in excess of this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ESG aspects and has therefore committed itself to the guidelines of the UN PRI. SHS is currently investing from its sixth fund, which was launched in 2022 and has a volume of ca. € 250 million.
More information at: www.shs-capital.eu
Are you interested in receiving regular updates about SHS? Subscribe to our Newsletter
and follow us on LinkedIn
Pressekontakt:
Sarah Stelzer
SHS Gesellschaft für Beteiligungsmanagement mbH
Bismarckstraße 12
72072 Tübingen
sas@shs-capital.eu